Business context and reporting period
The supplied filing is FibroGen, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2018, filed May 9, 2018. This does not match the request metadata naming Kyntra Bio, Inc.; verify the issuer before relying on this summary. FibroGen is a clinical-stage biopharmaceutical company whose revenue is primarily from collaborations. Its lead candidate, roxadustat, was in Phase 3 development for anemia in chronic kidney disease (CKD) and myelodysplastic syndromes (MDS); pamrevlumab was in Phase 2 for idiopathic pulmonary fibrosis, pancreatic cancer, and Duchenne muscular dystrophy.
Financial performance and position
| Metric | Q1 2018 | Q1 2017 |
|---|---|---|
| Revenue | $31.9 million | $29.4 million |
| Research and development expense | $57.0 million | $46.7 million |
| General and administrative expense | $15.6 million | $11.5 million |
| Total operating expenses | $72.5 million | $58.3 million |
| Operating loss | $40.6 million | $28.8 million |
| Net loss | $41.4 million | $30.6 million |
| Net loss per share, basic and diluted | $0.50 | $0.48 |
| Net cash used in operating activities | $32.0 million | $27.1 million |
Revenue was entirely development and other revenue; no license revenue or product sales were reported. The company reported no gross profit or gross margin figure. Cash and cash equivalents were $659.0 million at March 31, 2018, and investments totaled $55.3 million; accounts receivable was $10.0 million. The filing reports $724.2 million in cash, cash equivalents, investments, and accounts receivable combined. Current assets were $717.2 million against current liabilities of $83.3 million. Total liabilities were $348.8 million, including $97.6 million of long-term lease financing obligations, $17.8 million of product development obligations, and $154.9 million of deferred revenue. Accumulated deficit was $670.8 million.
Material changes versus the prior comparable period
- Revenue increased $2.5 million, or 8%, primarily from higher roxadustat co-development billings: AstraZeneca revenue rose 8% and Astellas revenue rose 10%.
- Operating expenses increased $14.3 million, or 24%. R&D rose 22%, led by roxadustat spending, employee costs, facilities, and stock-based compensation; G&A rose 35%, primarily from personnel, facilities, and stock-based compensation.
- Net loss widened by $10.8 million to $41.4 million. Higher revenue and improved net interest and other expense partly offset higher operating costs.
- Operating cash use increased by $4.8 million. Cash and cash equivalents declined $14.7 million from year-end; cash, investments, and receivables combined declined $30.5 million.
Outlook, commentary, and risks
Management expected to complete enrollment in U.S. roxadustat CKD Phase 3 studies in Q2 2018, report topline results in Q4 2018, and submit a U.S. NDA in the first half of 2019 after pooled safety data. A China CKD anemia approval decision was anticipated by year-end 2018; Astellas expected a Japan NDA submission for dialysis-dependent CKD anemia in 2018. FibroGen expected FDA feedback on a Phase 3 IPF plan and agreement on a pivotal pancreatic cancer trial design by mid-2018. It completed enrollment in a 21-patient Phase 2 DMD study.
Management stated existing cash, investments, and receivables were expected to fund anticipated requirements for at least 12 months from the filing date, while warning that assumptions could change and additional financing might be needed. The company anticipated continued losses and rising R&D costs, and had no product-sales revenue. Key uncertainties include Phase 3 efficacy and safety, regulatory review and approval, manufacturing readiness and supply, collaboration-partner performance or termination, competition, reimbursement and pricing, and China regulatory, distribution, and operating risks. Roxadustat’s interaction with statins and the need to establish commercial manufacturing and market access are also disclosed risks.
FibroGen adopted ASC 606 on January 1, 2018 using the full retrospective method, recasting prior-period results. The recast increased Q1 2017 revenue by $2.6 million and changed the timing and classification of collaboration revenue; it did not affect previously reported cash flows. Management reported effective disclosure controls as of March 31, 2018, no material change in internal control, and no material legal proceedings.
Important facts for investors to verify
- Confirm that FibroGen, rather than Kyntra Bio, is the intended issuer and that the 2018 Q1 period is correct.
- Track roxadustat trial enrollment, topline data, safety analyses, and regulatory timing against the stated milestones.
- Assess the assumptions behind collaboration revenue recognition, including co-development billings, deferred revenue, and China’s deferred performance obligation.
- Monitor operating cash burn, trial spending, liquidity, and whether management’s stated 12-month funding outlook remains valid.
- Verify manufacturing-facility certification, commercial supply arrangements, and the status of regulatory and market-access requirements in China.